Loading data for GUTS — first visit, this takes a few seconds.
Fractyl Health Inc. (GUTS)
NasdaqGM: GUTS
· Real-Time Price · USD
0.72
+0.06 (9.09%)
At close: Aug 18, 2026, 8:00 PM
0.76
+5.84%
Pre-market: 4:33 AM
Fractyl Health Inc. (GUTS) Stock Price, Analysis & Data
9.09% (1D)
No data available
| Bid | n/a |
| Market Cap | 114.15M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -105.65M |
| Beta | 2.32 |
| EPS (ttm) | -0.99 |
| PE Ratio (ttm) | n/a |
| Forward PE | -1.64 |
| P/B (ttm) | 5.31 |
| P/S (ttm) | n/a |
| Earnings Date | Nov 11, 2026 |
| Ask | n/a |
| Volume | 1,521,512 |
| Avg. Volume (20D) | 1,621,187 |
| Open | 0.66 |
| Previous Close | 0.66 |
| Day's Range | 0.66 - 0.75 |
| 52-Week Range | 0.38 - 2.44 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About GUTS
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. It develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. The company also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene ...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 2, 2024
Employees 100
Stock Exchange NasdaqGM
Ticker Symbol GUTS
Website https://fractyl.com
Financial Performance
In 2025, Fractyl Health's revenue was 0, a decrease of -100% compared to the previous year's 93K. Earnings were -140.95M, an increase of 105.19%.
Financial StatementsEarnings Surprise
Fractyl Health has released their quarterly earnings on Aug 10, 2026:
Fractyl Health Inc. is scheduled to release its earnings on Nov 11, 2026, during market hours.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2